NCT06263153View on ClinicalTrials.gov

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Bladder Urothelial CarcinomaMuscle Invasive Bladder CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

BIOLOGICAL

Durvalumab

Given IV

DRUG

Futibatinib

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Radical Cystectomy

Undergo radical cystectomy

Trial Locations (3)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

44195

RECRUITING

Cleveland Clinic Taussig Cancer Center, Cleveland

48109

RECRUITING

University of Michigan Comprehensive Cancer Center, Ann Arbor

All Listed Sponsors
collaborator

Gateway for Cancer Research

OTHER

lead

Yuanquan Yang

OTHER